Patent Evaluation: Benzanilide derivatives as 5-HT_1D antagonists

Summary

Novelty: Novel benzanilide derivatives are claimed to be 5-HT₁₀ antagonists. They are potentially useful for the treatment of depression, Parkinson's disease and a variety of CNS disorders including anxiety, panic and memory disorders.

Biology: No biological data are disclosed.

Chemistry: A total of forty-six final compounds and fifty-one intermediates are disclosed. Syntheses are given in all cases. Yields, mps and some ¹H nmr data are given. Twenty-five compounds are specifically claimed including 4′-cyano-N4-methoxy-3-(4-methyl-1-piperazinyl)phenyl]-2′-methyl-[1,1′-biphenyl]-4-carboxamide.